Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse.
about
Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversionAgonist Medications for the Treatment of Cocaine Use DisorderManagement of fibromyalgia syndrome: review of evidence.Behavioral effects of gamma-hydroxybutyrate in humansSodium oxybate for the treatment of fibromyalgia.The use of sodium oxybate to treat narcolepsy.Intravenous self-administration of γ-hydroxybutyrate (GHB) in baboonsA web-based study of gamma hydroxybutyrate (GHB): patterns, experiences, and functions of use.GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome.Preference for gamma-hydroxybutyrate (GHB) in current users.Pharmacodynamic interactions of a solid formulation of sodium oxybate and ethanol in healthy volunteers.Self-administration of gamma-hydroxybutyric acid (GHB) precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) in baboonsPhysical dependence on gamma-hydroxybutrate (GHB) prodrug 1,4-butanediol (1,4-BD): time course and severity of withdrawal in baboons.Illicit substance use in pregnancy - a review.Management of fibromyalgia syndrome in 2016.Cognitive, psychomotor, and subjective effects of sodium oxybate and triazolam in healthy volunteersLong-term tolerability and maintenance of therapeutic response to sodium oxybate in an open-label extension study in patients with fibromyalgiaReconsidering GHB: orphan drug or new model antidepressant?Potential impact of drug effects, availability, pharmacokinetics, and screening on estimates of drugs implicated in cases of assault.Screening and confirmation methods for GHB determination in biological fluids.Pharmacological Treatment in γ-Hydroxybutyrate (GHB) and γ-Butyrolactone (GBL) Dependence: Detoxification and Relapse Prevention.Feasibility of following up gamma-hydroxybutyric acid concentrations in sodium oxybate (Xyrem®)-treated narcoleptic patients using dried blood spot sampling at home: an exploratory study.Synthesis and stability study of a new major metabolite of γ-hydroxybutyric acidNovel Psychoactive Substances-Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs.Intoxication with GHB/GBL: characteristics and trends from ambulance-attended overdoses.Risk factors of γ-hydroxybutyrate overdosing.Barriers To Research Using Controlled Drugs Are Not Created Equal.Sodium oxybate to treat alcohol dependence: 20 years of clinical experience.Effect of chronic γ-hydroxybutyrate (GHB) administration on GHB toxicokinetics and GHB-induced respiratory depression.Substitution therapy for alcoholism: time for a reappraisal?Dried blood spot punches for confirmation of suspected γ-hydroxybutyric acid intoxications: validation of an optimized GC-MS procedure.Effect of GHB-use and GHB-induced comas on dorsolateral prefrontal cortex functioning in humans
P2860
Q24653625-FBF58874-072D-4757-976C-ADE4C82349D6Q28087404-891FA7F6-D433-4558-B636-44819709FF2EQ33938302-7F938193-004D-478F-83B5-9D057AE56CF8Q34026042-0B4A7A53-71B1-4A35-A85D-6E2D086DD70BQ34193082-20E7F844-0917-4EA2-93E1-D9E7CED07193Q34272284-7A732A73-8227-4F2A-93A2-CB66E61B5CD1Q34630587-29F56E3D-CA35-4B29-BBBD-07CA052157C5Q34730168-0FCFD3AA-A6BD-4B39-BFBB-7D95036F932DQ35710620-CC73791A-38DB-4B09-BF7B-7C3A97E84B83Q36025811-6A8E9CF9-72BB-4658-ABC2-B4AF5772A294Q36072485-D9FD7F73-4FDD-4158-98D7-996AC0726DE0Q36539839-4E7CDCA9-DA8F-4242-943F-EF2602BCE761Q37033882-371450C7-7074-4D74-9748-5066E9348A85Q37185873-B7873DF4-FF17-41D6-8A81-E8D994D70C1FQ37342832-7A00A1DC-F129-401A-9FEB-323FCC39AE47Q37472845-031CFD79-831C-4D75-A5CF-A5831DBD1A23Q37690358-06280945-1BD1-4C64-9A9E-AAB310458399Q37934335-2AB90638-28C2-4EF1-9BF6-FE17EA1DF57AQ37940945-6CC35243-1E3A-40C5-AE7E-EA07D0C4B607Q38185603-FE6A08BA-1359-495D-B9FD-F9AC8F767C90Q39048315-65E509E0-8F13-40E6-A303-4B865DD88EB1Q39456871-3A5A09BF-FC5C-427C-9687-2714CED0E306Q39903404-B1BEB900-6708-4333-9CA7-A271384F873DQ41462770-C028D56D-DC9C-48D8-9A00-A9A1C606A2D5Q42183368-EAE815B9-4273-4F7D-AC23-CABC410B01E8Q43883628-BAC56730-59F0-43FB-A2BA-0160B3CC9BCAQ45029630-D2190CDB-94B7-4660-974F-84F8EE8FAACEQ45798267-7FF70541-E941-4A80-AB6C-0C0E971A128FQ47841359-AD907BA2-C22E-4398-B754-D209EC66CF37Q48248695-4DDE6F5A-08D4-40A8-BEDA-A9C985E29365Q49044992-AE8D0920-4AA5-41CA-B7B2-41BB1DD6557BQ57299896-CE4D268B-819B-4952-853A-9CD88B1B50CA
P2860
Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Illicit gamma-hydroxybutyrate ...... in characteristics and misuse.
@en
Illicit gamma-hydroxybutyrate
@nl
type
label
Illicit gamma-hydroxybutyrate ...... in characteristics and misuse.
@en
Illicit gamma-hydroxybutyrate
@nl
prefLabel
Illicit gamma-hydroxybutyrate ...... in characteristics and misuse.
@en
Illicit gamma-hydroxybutyrate
@nl
P2093
P2860
P1476
Illicit gamma-hydroxybutyrate ...... in characteristics and misuse.
@en
P2093
Daniel Pardi
Jane Gorsline
Lawrence P Carter
Roland R Griffiths
P2860
P356
10.1016/J.DRUGALCDEP.2009.04.012
P577
2009-06-02T00:00:00Z